Biologics/Immunotherapy News

Researchers found no skin and soft tissue infection or systemic infections after administering more than 130,000 allergen immunotherapy treatments to patients at Massachusetts General Hospital and Brigham and Women’s Hospital, according to a recent study published in The Journal of Allergy and Clinical Immunology.

Use of a grass sublingual immunotherapy tablet concomitantly with subcutaneous or sublingual immunotherapy appeared safe and tolerable in patients undergoing allergy immunotherapy, according to recent research.

Although the mortality rate for patients undergoing subcutaneous immunotherapy has decreased, researchers still recommend careful selection for patients with modifiable risk factors, according to recent research.

Patients who underwent subcutaneous immunotherapy experienced a low frequency of systemic reactions, but researchers recommended determining predisposing factors to reactions before implementing immunotherapy, according to recent research.

LOS ANGELES — Jonathan M. Spergel, MD, PhD, chief of the allergy section at the Children’s Hospital of Philadelphia, outlined results of the multicenter MILES trial, which indicated that Viaskin Milk Epicutaneous Immunotherapy was well tolerated by patients aged two to 17 years with an IgE-mediated cow’s milk protein allergy.

LOS ANGELES — Joseph L. Baumert, PhD, from the Food Allergy Research and Resource Program, at the University of Nebraska-Lincoln, discusses safety benefits linked to increased clinical peanut thresholds through immunotherapy.

LOS ANGELES — A higher rate of systemic reactions in pediatric patients is associated with subcutaneous immunotherapy, according to recent study data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

LOS ANGELES — A universal policy requiring patients to have autoinjectable epinephrine with them while receiving subcutaneous immunotherapy will enhance safety, according to a recent study presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

Patients who received an escalated dosage of subcutaneous immunotherapy across a decreased number of weekly injections tolerated the escalation well with a good safety profile, according to results from an open label phase 2 trial.

Subcutaneous immunotherapy is effective in treating the symptoms of seasonal allergy rhinitis and grass pollen allergies in the elderly, according to recent research.